Expiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
Senator Bernie Sanders accuses Ozempic and Wegovy maker of ‘ripping off’ Americans
Complaint alleges pharmacy benefit managers owned by CVS, Cigna and UnitedHealth are keeping prices high
US telehealth groups including Hims & Hers and Ro could find new revenue streams under threat
US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
Easing the squeeze on the share of health spending that goes on medicine may alleviate pain
Spending watchdog declines to give green light to lecanemab for patients in England
Administration claims victory in talks to cut the costs of 10 critical medicines
Drugmakers will receive flat fees for new medicines in push to avoid encouraging overuse
Nice blames cost for not recommending Enhertu, which has helped patients in clinical trials live longer
Swiss drugmaker says it will only sell medication privately if health systems cannot pay
New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Alcohol, food, tobacco and fossil fuel sectors oppose efforts to target conditions linked to 2.7mn deaths a year, warns WHO
People with cystic fibrosis, epilepsy and diabetes among those struggling with medicine shortages
As the health benefits of anti-obesity medicines widen, pharma companies need to rethink what they charge
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value
US pharma group follows Eli Lilly with website for patients to obtain medication online
US state to buy naloxone nasal spray from generics maker and distribute medication under its own brand
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Success of biosimilars in lowering prices will depend on decisions from powerful pharmacy benefit managers
Lenmeldy gene therapy treats MLD, a condition that attacks the central nervous system of young children
Chief executive says customers very willing to pay for Wegovy from their own pockets
US reforms will put Big Pharma under pressure but innovative companies will retain their pricing power
Danish drugmaker reports better than expected earnings for 2023
